Related Experiment Video
Updated: Dec 7, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.0K
How to Capture the Bleeding Phenotype in FXI-Deficient Patients
Debora Bertaggia Calderara1, Maxime G Zermatten1, Alessandro Aliotta1
1Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Hamostaseologie
|October 1, 2020
Summary
Factor XI (FXI) deficiency causes variable bleeding, and current tests don't predict risk. Global coagulation assays are being explored to better understand FXI's role in hemostasis and guide treatment.
Area of Science:
- Biochemistry
- Hematology
- Genetics
Background:
- Factor XI (FXI) is crucial for blood clot stability.
- Mutations in the F11 gene cause FXI deficiency, a mild bleeding disorder.
- Current assays cannot reliably predict bleeding risk in FXI-deficient patients.
Purpose of the Study:
- To review the function of FXI and its deficiency.
- To explore novel global coagulation assays for assessing FXI's role in hemostasis.
- To identify methods for better understanding FXI deficiency phenotypes.
Main Methods:
- Review of existing literature on Factor XI.
- Discussion of global coagulation assays.
- Analysis of research methods investigating FXI function.
Main Results:
- FXI's role in coagulation propagation and clot stability is complex.
- Bleeding tendency in FXI deficiency is not correlated with plasma FXI activity.
- Global assays show promise in evaluating hemostatic potential.
Conclusions:
- Accurate assessment of hemostatic potential is vital for managing FXI deficiency.
- Global coagulation assays offer a potential alternative to traditional methods.
- Further research is needed to refine these assays for clinical application.
